Aurobindo Pharma Launched ADQUEY Ointment in US
The pharmaceutical company entered the dermatology market with a topical treatment for atopic dermatitis.
Updated on Oct. 14, 2026 in Healthcare
Live Poll
Do you trust that shifting toward specialty pharmaceuticals will benefit patients' access to affordable medicine?
Aurobindo Pharma has officially launched ADQUEY, a 1 percent difamilast topical ointment, to treat mild-to-moderate atopic dermatitis in the United States. The company is managing this product rollout through its subsidiary, Acrotech Biopharma.
Why it matters
Aurobindo is shifting its business focus toward specialty medicines to escape the intense price competition and consolidation affecting traditional generic drug markets. Specialty products offer higher margins and greater stability than generic alternatives.
Aurobindo expects ADQUEY to generate between $200 million and $300 million in revenue over the next 3 to 4 years. The company is targeting a segment of the US dermatology market currently valued at approximately $1.3 billion.
The players
Aurobindo Pharma
An international pharmaceutical manufacturer based in India that produces a wide range of generic and specialty medications.
Acrotech Biopharma
A subsidiary of Aurobindo Pharma that specializes in the marketing of proprietary and innovative medicines in the United States.
Otsuka Pharmaceutical
A global healthcare company headquartered in Japan that focuses on the research and development of pharmaceutical products.
The details
Licensed from Japan-based Otsuka Pharmaceutical, ADQUEY is a non-steroidal treatment for skin inflammation. To support the launch, Acrotech Biopharma established a dedicated sales and physician engagement platform specifically for the dermatology sector.
Timeline
October 14, 2026: The launch of the product was announced.
Next 3-4 years: The timeframe during which the product is expected to generate its projected revenue.
Market Landscape
Aurobindo is following a strategic pattern set by the industry-wide move from generic drug manufacturing to high-value specialty medicine franchises. This pivot positions the firm to compete in a sector where companies like Sun Pharma have already established significant market scale.
Patients suffering from atopic dermatitis may soon have access to this new topical treatment as it becomes available through physician channels. The launch represents a new option in a $1.3 billion market, potentially expanding the range of available non-steroidal dermatological therapies.
The takeaway
The move underscores the growing preference for specialty medicines that offer clearer profitability than saturated generic markets. Investors and clinicians should monitor how this new portfolio segment grows alongside the company's planned expansion into respiratory treatments.
Further reading
For more on the current state of the industry, visit the Healthcare section.
Source note: This article includes information reported by MoneyControl.
Live Poll
Do you trust that shifting toward specialty pharmaceuticals will benefit patients' access to affordable medicine?
